Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
TERMINATED
Clinical Phase
EARLY_PHASE1
Total Enrollment
19 participants
Study Classification
INTERVENTIONAL
Study Start Date
2011-06-30
Study Completion Date
2016-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study is to contribute evidence towards the potential to improve cognition in HIV+ individuals experiencing cognitive decline through personalized change in antiretroviral (ARV) medication. To that end, following a comprehensive evaluation to identify confounding clinical conditions, study participants will undergo a lumbar puncture to: (i) measure viral load (at 2 copies/ml); (ii) identify Cerebrospinal Fluid (CSF) genotype and tropism; and (iii) measure concentration of antiretroviral agents. When indicated from the CSF analysis, a personalized change in ARV will be implemented. Cognition will be measured in all at study entry and 6 months later.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Neurocognitive Sub-study of Encore1
NCT01516060
HIV
COMPLETED
PHASE3
Neurocognitive Function Improvement After Switching From Efavirenz to Rilpivirine
NCT03567304
HIV-1-infection
Neurocognitive Dysfunction
UNKNOWN
PHASE4
A Study of the Neurological Effects of Adding Raltegravir to HAART Regimen in Patients With HIV
NCT01448486
Human Immunodeficiency Virus (HIV)
HIV Associated Neurocognitive Disorders (HAND)
TERMINATED
PHASE4
Switching From Efavirenz/Atripla to Rilpivirine Among Patients With Neurocognitive or Neuropsychological Side Effects
NCT02042001
Impaired Cognition
Depression/Anxiety
Poor Quality Sleep
+2 more
COMPLETED
PHASE4
Study to Compare the Virologic Efficacy in Cerebrospinal Fluid (CSF) and Neurocognitive State in Patients Infected by HIV-1 Long-term Treatment (> 3 Years) With Lopinavir / Ritonavir Monotherapy
NCT01116817
HIV
COMPLETED
PHASE4
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
HIV - Human Immunodeficiency Virus
Cognitive Symptoms
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Change in ARVs to improve cognition
Change in ARVs to improve cognition: Personalized change in antiretrovirals will be based on CSF analysis
Group Type
EXPERIMENTAL
Change in antiretrovirals
Intervention Type
DRUG
Change in ARVs to improve cognition: Personalized change in antiretrovirals will be based on CSF analysis
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Change in antiretrovirals
Change in ARVs to improve cognition: Personalized change in antiretrovirals will be based on CSF analysis
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* are 18 years and older
* have the capacity to give informed consent as determined by the research nurse
* have unexplained cognitive decline (reported either by the patient or an outside informant)
* have been on a stable ART regimen for \> 6 months
* have an undetectable viral load in plasma for at least 6 months (a single blip of ≤ 150 copies/mL will be accepted)
* have not had a change in medications that could potentially interfere with cognition in the past 4 months
* have the capacity to give informed consent as determined by the research nurse
* have unexplained cognitive decline (reported either by the patient or an outside informant)
* have been on a stable ART regimen for \> 6 months
* have an undetectable viral load in plasma for at least 6 months (a single blip of ≤ 150 copies/mL will be accepted)
* have not had a change in medications that could potentially interfere with cognition in the past 4 months
Exclusion Criteria
* detectable VL in the plasma
* past history of dementia
* past history of Central Nervous System opportunistic infection or stroke
* current substance abuse ( as per DSM-IV criteria) other than cigarettes
* coagulopathy
* thrombocytopenia
* use of Coumadin
* intra-cranial hypertension
* past history of dementia
* past history of Central Nervous System opportunistic infection or stroke
* current substance abuse ( as per DSM-IV criteria) other than cigarettes
* coagulopathy
* thrombocytopenia
* use of Coumadin
* intra-cranial hypertension
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fonds de la Recherche en Santé du Québec
OTHER_GOV
Sponsor Role
collaborator
CIHR Canadian HIV Trials Network
NETWORK
Sponsor Role
collaborator
Marie-Josée Brouillette
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Marie-Josée Brouillette
Associate Professor
Responsibility Role
SPONSOR_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marie-Josée Brouillette, MD, FRCPC
Role: PRINCIPAL_INVESTIGATOR
Montreal Chest Institute - Chronic Viral Illness Service - McGill University Health Centre (MUHC)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Montreal Chest Institute - Chronic Viral Illness Service - McGill University Health Centre (MUHC)
Montreal, Quebec, Canada
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Canada
References
Explore related publications, articles, or registry entries linked to this study.
Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007 Oct 30;69(18):1789-99. doi: 10.1212/01.WNL.0000287431.88658.8b. Epub 2007 Oct 3.
Reference Type
BACKGROUND
Morrison NE, Collins FM. Immunogenicity of an aerogenic BCG vaccine in T-cell-depleted and normal mice. Infect Immun. 1975 May;11(5):1110-21. doi: 10.1128/iai.11.5.1110-1121.1975.
Reference Type
BACKGROUND
Becker JT, Lopez OL, Dew MA, Aizenstein HJ. Prevalence of cognitive disorders differs as a function of age in HIV virus infection. AIDS. 2004 Jan 1;18 Suppl 1:S11-8.
Reference Type
BACKGROUND
Canestri A, Lescure FX, Jaureguiberry S, Moulignier A, Amiel C, Marcelin AG, Peytavin G, Tubiana R, Pialoux G, Katlama C. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis. 2010 Mar 1;50(5):773-8. doi: 10.1086/650538.
Reference Type
BACKGROUND
Carey CL, Woods SP, Gonzalez R, Conover E, Marcotte TD, Grant I, Heaton RK; HNRC Group. Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol. 2004 May;26(3):307-19. doi: 10.1080/13803390490510031.
Reference Type
BACKGROUND
Cherner M, Ellis RJ, Lazzaretto D, Young C, Mindt MR, Atkinson JH, Grant I, Heaton RK; HIV Neurobehavioral Research Center Group. Effects of HIV-1 infection and aging on neurobehavioral functioning: preliminary findings. AIDS. 2004 Jan 1;18 Suppl 1:S27-34.
Reference Type
BACKGROUND
Cysique LA, Vaida F, Letendre S, Gibson S, Cherner M, Woods SP, McCutchan JA, Heaton RK, Ellis RJ. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology. 2009 Aug 4;73(5):342-8. doi: 10.1212/WNL.0b013e3181ab2b3b. Epub 2009 May 27.
Reference Type
BACKGROUND
Cysique LA, Brew BJ. Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: a review. Neuropsychol Rev. 2009 Jun;19(2):169-85. doi: 10.1007/s11065-009-9092-3. Epub 2009 May 9.
Reference Type
BACKGROUND
Cysique LA, Maruff P, Brew BJ. Variable benefit in neuropsychological function in HIV-infected HAART-treated patients. Neurology. 2006 May 9;66(9):1447-50. doi: 10.1212/01.wnl.0000210477.63851.d3.
Reference Type
BACKGROUND
De Luca A, Ciancio BC, Larussa D, Murri R, Cingolani A, Rizzo MG, Giancola ML, Ammassari A, Ortona L. Correlates of independent HIV-1 replication in the CNS and of its control by antiretrovirals. Neurology. 2002 Aug 13;59(3):342-7. doi: 10.1212/wnl.59.3.342.
Reference Type
BACKGROUND
Ellis RJ, Moore DJ, Childers ME, Letendre S, McCutchan JA, Wolfson T, Spector SA, Hsia K, Heaton RK, Grant I. Progression to neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA. Arch Neurol. 2002 Jun;59(6):923-8. doi: 10.1001/archneur.59.6.923.
Reference Type
BACKGROUND
Florkowski CM. Sensitivity, specificity, receiver-operating characteristic (ROC) curves and likelihood ratios: communicating the performance of diagnostic tests. Clin Biochem Rev. 2008 Aug;29 Suppl 1(Suppl 1):S83-7.
Reference Type
BACKGROUND
Hardy DJ, Vance DE. The neuropsychology of HIV/AIDS in older adults. Neuropsychol Rev. 2009 Jun;19(2):263-72. doi: 10.1007/s11065-009-9087-0. Epub 2009 Feb 27.
Reference Type
BACKGROUND
McCutchan JA, Wu JW, Robertson K, Koletar SL, Ellis RJ, Cohn S, Taylor M, Woods S, Heaton R, Currier J, Williams PL. HIV suppression by HAART preserves cognitive function in advanced, immune-reconstituted AIDS patients. AIDS. 2007 May 31;21(9):1109-17. doi: 10.1097/QAD.0b013e3280ef6acd.
Reference Type
BACKGROUND
Jones RN, Gallo JJ. Dimensions of the Mini-Mental State Examination among community dwelling older adults. Psychol Med. 2000 May;30(3):605-18. doi: 10.1017/s0033291799001853.
Reference Type
BACKGROUND
Koski L, Xie H, Finch L. Measuring cognition in a geriatric outpatient clinic: Rasch analysis of the Montreal Cognitive Assessment. J Geriatr Psychiatry Neurol. 2009 Sep;22(3):151-60. doi: 10.1177/0891988709332944. Epub 2009 Mar 23.
Reference Type
BACKGROUND
Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, Gelman BB, McArthur JC, McCutchan JA, Morgello S, Simpson D, Grant I, Ellis RJ; CHARTER Group. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008 Jan;65(1):65-70. doi: 10.1001/archneurol.2007.31.
Reference Type
BACKGROUND
Letendre SL, McCutchan JA, Childers ME, Woods SP, Lazzaretto D, Heaton RK, Grant I, Ellis RJ; HNRC Group. Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann Neurol. 2004 Sep;56(3):416-23. doi: 10.1002/ana.20198.
Reference Type
BACKGROUND
Marra CM, Lockhart D, Zunt JR, Perrin M, Coombs RW, Collier AC. Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapy. Neurology. 2003 Apr 22;60(8):1388-90. doi: 10.1212/01.wnl.0000058768.73358.1a.
Reference Type
BACKGROUND
Marra CM, Zhao Y, Clifford DB, Letendre S, Evans S, Henry K, Ellis RJ, Rodriguez B, Coombs RW, Schifitto G, McArthur JC, Robertson K; AIDS Clinical Trials Group 736 Study Team. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS. 2009 Jul 17;23(11):1359-66. doi: 10.1097/QAD.0b013e32832c4152.
Reference Type
BACKGROUND
Nath A, Sacktor N. Influence of highly active antiretroviral therapy on persistence of HIV in the central nervous system. Curr Opin Neurol. 2006 Aug;19(4):358-61. doi: 10.1097/01.wco.0000236614.51592.ca.
Reference Type
BACKGROUND
Nilsson C, Stahlberg F, Thomsen C, Henriksen O, Herning M, Owman C. Circadian variation in human cerebrospinal fluid production measured by magnetic resonance imaging. Am J Physiol. 1992 Jan;262(1 Pt 2):R20-4. doi: 10.1152/ajpregu.1992.262.1.R20.
Reference Type
BACKGROUND
Pilcher CD, Shugars DC, Fiscus SA, Miller WC, Menezes P, Giner J, Dean B, Robertson K, Hart CE, Lennox JL, Eron JJ Jr, Hicks CB. HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health. AIDS. 2001 May 4;15(7):837-45. doi: 10.1097/00002030-200105040-00004.
Reference Type
BACKGROUND
Price RW, Yiannoutsos CT, Clifford DB, Zaborski L, Tselis A, Sidtis JJ, Cohen B, Hall CD, Erice A, Henry K. Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy. AIDS Clinical Trial Group and Neurological AIDS Research Consortium study team. AIDS. 1999 Sep 10;13(13):1677-85. doi: 10.1097/00002030-199909100-00011.
Reference Type
BACKGROUND
Robertson KR, Smurzynski M, Parsons TD, Wu K, Bosch RJ, Wu J, McArthur JC, Collier AC, Evans SR, Ellis RJ. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS. 2007 Sep 12;21(14):1915-21. doi: 10.1097/QAD.0b013e32828e4e27.
Reference Type
BACKGROUND
Robertson KR, Robertson WT, Ford S, Watson D, Fiscus S, Harp AG, Hall CD. Highly active antiretroviral therapy improves neurocognitive functioning. J Acquir Immune Defic Syndr. 2004 May 1;36(1):562-6. doi: 10.1097/00126334-200405010-00003.
Reference Type
BACKGROUND
Schultz-Larsen K, Kreiner S, Lomholt RK. Mini-Mental Status Examination: mixed Rasch model item analysis derived two different cognitive dimensions of the MMSE. J Clin Epidemiol. 2007 Mar;60(3):268-79. doi: 10.1016/j.jclinepi.2006.06.007. Epub 2006 Aug 10.
Reference Type
BACKGROUND
Valcour V, Shikuma C, Shiramizu B, Watters M, Poff P, Selnes O, Holck P, Grove J, Sacktor N. Higher frequency of dementia in older HIV-1 individuals: the Hawaii Aging with HIV-1 Cohort. Neurology. 2004 Sep 14;63(5):822-7. doi: 10.1212/01.wnl.0000134665.58343.8d.
Reference Type
BACKGROUND
Valcour V, Paul R. HIV infection and dementia in older adults. Clin Infect Dis. 2006 May 15;42(10):1449-54. doi: 10.1086/503565. Epub 2006 Apr 13.
Reference Type
BACKGROUND
Wouters H, van Gool WA, Schmand B, Lindeboom R. Revising the ADAS-cog for a more accurate assessment of cognitive impairment. Alzheimer Dis Assoc Disord. 2008 Jul-Sep;22(3):236-44. doi: 10.1097/WAD.0b013e318174f8b9.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CTNPT 015
Identifier Type: -
Identifier Source: org_study_id
NCT01848678
Identifier Type: -
Identifier Source: nct_alias
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Effect of Cobicistat Versus Ritonavir Boosting on the Brain Permeation of Darunavir in HIV-infected Individuals
NCT02503462
TERMINATED
PHASE4
Cognitive Therapy in Patients Failing ART
NCT03751046
COMPLETED
NA
Modulation of Monocyte Activation by Atorvastatin in HIV Infection
NCT01263938
COMPLETED
PHASE4
Efficacy and Safety of Two Pharmacologic Strategies on Neurocognitive Impairment in HIV Infection. The TRIANT-TE Study
NCT01348282
COMPLETED
PHASE4
Phase I/II, Open-Label Trial of Three Monoclonal Antibodies
NCT00219986
COMPLETED
PHASE1/PHASE2
Cohort of Patients Naive of Antiretroviral Treatment at Enrollment
NCT03137797
COMPLETED
Effect of Cytoreductive Chemotherapy and a CCR5 Coreceptor Antagonist on HIV-1 Eradication
NCT02486510
TERMINATED
EARLY_PHASE1
Using Less Neurotoxic Drugs in Patients With HAND (MARAND-X)
NCT03163277
TERMINATED
PHASE4
An Extension of Protocol PRO 140_CD01 Study
NCT02355184
TERMINATED
PHASE2
Study in HIV1-Positive, Virosuppressed Patients Currently inTreatment With Ritonavir-Boosted Protease Inhibitors (PI/r) Starting Cobicistat-Boosted Darunavir (DRV/c - Rezolsta)
NCT02926456
COMPLETED
Evaluation of Maraviroc Intensification in HIV Infected Patients With Insufficient Immune Restoration
NCT00944541
COMPLETED
PHASE2
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
NCT01363011
COMPLETED
PHASE3
Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
NCT01440569
COMPLETED
PHASE3
A Study to Evaluate the Safety of the HIV-1 Vaccine MVA-B in Chronic HIV-1 Infected Patients Successfully Treated With HAART
NCT01571466
COMPLETED
PHASE1
A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1
NCT01266902
COMPLETED
PHASE3
Ex Vivo Characterization and Targeting of the Latent HIV Infected Reservoir to Cure HIV
NCT05215704
RECRUITING
Safety and Efficacy Clinical Study of KL-HIV-Tri01 in the Treatment of HIV Infected Subjects
NCT06117657
NOT_YET_RECRUITING
EARLY_PHASE1
Accurate Staging of Immuno-virological Dynamics During Acute HIV Infection
NCT03449706
RECRUITING
Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients
NCT01348308
COMPLETED
PHASE3
Switching the Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) or Protease Inhibitor (PI) to Maraviroc in HIV Subjects
NCT00966329
COMPLETED
PHASE4
Cohort Study of HIV-positive People, Treated With Long Acting Antiretroviral Therapy
NCT05663580
RECRUITING
Advanced Neuroimaging Evaluation of CNS Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen
NCT01978743
COMPLETED
NA
Early Intensification of Antiretroviral Therapy Including Enfuvirtide in HIV-1-Related Progressive Multifocal Leucoencephalopathy (ANRS125)
NCT00120367
COMPLETED
PHASE2
Early Antiviral Therapy for Critically Ill HIV Infected Patients
NCT01455688
COMPLETED
PHASE4